Treatment Characteristics and Real-World Progression-Free Survival in Patients with Unresectable Stage III NSCLC who Received Durvalumab After Chemoradiotherapy: Findings from the PACIFIC-R Study.
N. Girard, J. Bar, P. Garrido, M. Garassino +19 more
2022Journal of Thoracic Oncology237 citations Open access
Semantic Scholar

